Viral attack opens up new ways to treat bacterial infectionsNovember 19th, 2009 WASHINGTON - Viruses invade both humans and animals, but some of them target bacteria instead. Potentially, that opens up new ways to treat bacterial infections, says a new study.
FDA panel backs stronger benefit claims for inhaler drug Spiriva marketed by PfizerNovember 19th, 2009 FDA panel backs stronger benefits of SpirivaWASHINGTON — Federal health experts say an inhaler drug from a German drugmaker works well enough to carry bolder claims about reducing coughing, wheezing and other respiratory problems. The Food and Drug Administration's panel of lung specialists voted 11-1 to allow Boehringer Ingelheim to add new labeling about the benefits of Spiriva Handihaler, which is approved to treat lung disease.
New discovery may lead to improved asthma drugsNovember 18th, 2009 WASHINGTON - An international team of researchers have made a novel discovery that might open avenues for developing new treatments for chronic inflammatory diseases like psoriasis and asthma. They have identified a new type of immune cell that can be out of control in certain inflammatory diseases and worsen symptoms.
Scientists trace link between Alzheimer's, heart failureNovember 16th, 2009 WASHINGTON - Scientists have figured out the link between Alzhemier's disease and chronic heart failure, two leading causes of death. A team of US, Canadian and Italian bio-chemists and cardiologists, led by Johns Hopkins researchers, identified three changes in the chemical make-up of a key structural protein, called desmin, in dog's heart muscle cells.
Novel approach to tackle colon cancerNovember 14th, 2009 WASHINGTON - Scientists from Karolinska Institutet have suggested a new way of fighting colon cancer. They focussed their study on a group of signal proteins called EphB receptors.
Experimental drug cocktail may help fight antiviral-resistant swine fluOctober 28th, 2009 WASHINGTON - A cocktail of three drugs, already on the market, offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, say researchers. Mark Prichard, a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases, says that in laboratory testing, the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) and ribavirin showed a significant capacity to stop flu-virus growth.
World's fastest supercomputer to create largest HIV evolutionary treeOctober 28th, 2009 WASHINGTON - Scientists are using the Roadrunner supercomputer, which is the world's fastest supercomputer, to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas. The project is being led by Los Alamos National Laboratory and the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium.
Why antidepressants don't work for most peopleOctober 25th, 2009 WASHINGTON - More than half of the people who take anti-depressants never get relief. This is because the cause of depression has been oversimplified and drugs designed to treat it aim at the wrong target, according to a new study.
Ciggie smoke 'weakens lungs' natural defense against harmful pathogen'October 24th, 2009 WASHINGTON - Exposure to cigarette smoke might weaken immune cells' ability to remove bacterial infections from the lungs, specifically nontypeable Haemophilus influenzae (NTHI), a pathogen often associated with respiratory infections and the progression of respiratory disease, says a new study. NTHI has been found to cause invasive diseases such as meningitis, sinusitis, pneumonia, and bronchitis.
Why don't anti-depressants work for most people?October 24th, 2009 WASHINGTON - More than half the people who take anti-depressants seldom get relief. A bnew study says this is because drugs designed to treat depression aim at the wrong target.
New links between chronic rhinosinusitis, depression establishedOctober 8th, 2009 WASHINGTON - Depression can be a common result of chronic rhinosinusitis (CRS), according to a new research. The study has been presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting and OTO EXPO, in San Diego, CA.
Chronic rhinosinusitis patients prone to other chronic illnesses tooOctober 5th, 2009 WASHINGTON - Patients of chronic rhinosinusitis (CRS) are also prone to suffer from other chronic illnesses like asthma, hypertension and arthritis, according to a study. The study used the electronic records of 1,970,695 patients to determine whether there was a relationship between CRS and other chronic conditions.
Chronic rhinosinusitis patients going for alternative medicineOctober 5th, 2009 WASHINGTON - An increasing number of patients are turning to complementary and alternative medical therapies to help treat the symptoms of chronic rhinosinusitis (CRS), revealed a new study. In the study, the researchers aimed to explore the pattern of complementary and alternative medicine (CAM) use in patients with a prior diagnosis of CRS at a rhinology outpatient clinic in Aberdeen, Scotland.
Drug combo better than individual medications for treating chronic painOctober 1st, 2009 WASHINGTON - A combination of two commonly prescribed drugs offers a much more effective treatment for people with debilitating neuropathic pain than if they take either of the medications individually, according to a study by Queen's University researchers. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain than when they took one or the other individually, reports Dr.
Drug-eluting stents safer than bare-metal ones for heart patientsSeptember 26th, 2009 WASHINGTON - A new study has shown that the use of a drug-eluting stent (paclitaxel) is safer and more effective than a bare-metal stent in heart attack patients. It also showed that administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.